10:46 AM EST - InMed Pharmaceuticals Inc. : Has filed Clinical Trial Applications in Austria, Israel and Serbia as part of a Phase 2 clinical trial of INM-755 (cannabinol) cream in Epidermolysis Bullosa. Additional CTAs for 755-201-EB (the ‘201 study) will be submitted to National Competent Authorities and Ethics Committees in France, Germany, Greece, and Italy in the coming weeks. InMed Pharmaceuticals Inc.
shares T.IN are trading up $0.33 at $4.39.
